Approved tesamorelin
As of September 2026, the current labels are EGRIFTA SV and EGRIFTA WR.
Forks in the road
The choices that change the whole path
A few early answers can prevent a long detour.
Checklist
Start with purpose
The reason for care comes before the format or price.
HIV with lipodystrophy
This is the condition named in the approved label.
General weight loss
As of September 2026, tesamorelin is not approved for this goal.
Fatty liver, memory, or ageing
These uses sit outside the approved label. Only a few small studies have looked at them, and their results do not make them approved uses.
An unclear promise
Pause and ask for the condition, the product, and the evidence in plain words.
Compare
Then check the product
The name on the offer changes the status and evidence questions.
A pharmacy-made “tesamorelin”
As of September 2026, tesamorelin counts in law as a biologic, a large protein medicine, and pharmacies have no legal route to copy it.
A research vial
A label saying “research use only” does not turn an online vial into medical care.